← Ablatotech Vitals
InfectiousDisease EvidenceDigest

Clinical management of infections in patients with hematologic malignancies undergoing CAR T-cell therapy

InfectiousDisease · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 4, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Patients with hematologic malignancies undergoing chimeric antigen receptor (CAR) T-cell therapy face substantial infection risks due to profound immunosuppression from lymphodepleting chemotherapy, CAR T-cell–induced cytopenias, and immune dysregulation. Early identification, prophylaxis, and tailored antimicrobial management are critical to mitigate morbidity and mortality. Emerging real-world data and expert consensus emphasize comprehensive infection surveillance, including fungal prophylaxis and dental evaluation, to optimize patient outcomes during the complex CAR T-cell therapy course.

Clinical bottom line

Patients with hematologic malignancies undergoing chimeric antigen receptor (CAR) T-cell therapy face substantial infection risks due to profound immunosuppression from lymphodepleting chemotherapy, CAR T-cell–induced cytopenias, and immune dysregulation. Early identification, prophylaxis, and tailored antimicrobial management are critical to mitigate morbidity and mortality. Emerging real-world data and expert consensus emphasize comprehensive infection surveillance, including fungal prophylaxis and dental evaluation, to optimize patient outcomes during the complex CAR T-cell therapy course.

What the evidence shows

Penack et al. (2024) provide a detailed overview of CAR T-cell therapy management in Germany, highlighting infection as a major complication. They report that bacterial infections predominate early post-infusion, while viral and fungal infections emerge later, correlating with prolonged neutropenia and hypogammaglobulinemia. Their findings underscore the need for vigilant infection monitoring and timely antimicrobial interventions.

Bupha-Intr et al. (2021) review infectious complications associated with CAR T-cell therapy, noting that cytokine release syndrome and neurotoxicity treatments (e.g., corticosteroids, tocilizumab) further increase infection susceptibility. They advocate for risk-adapted prophylaxis and prompt diagnostic evaluation to distinguish infection from inflammatory toxicities.

Özkocaman et al. (2026) discuss antifungal management in hematologic malignancy patients, including those receiving CAR T-cell therapy. They recommend primary antifungal prophylaxis in high-risk patients, empirical therapy guided by clinical and diagnostic criteria, and diagnosis-driven treatment to reduce fungal morbidity.

Zadik et al. (2025) emphasize the importance of dental evaluation and management prior to CAR T-cell therapy to prevent oral infections that can complicate immunosuppression. Their MASCC/ISOO clinical practice statement provides practical guidelines for dental clearance and ongoing oral care.

Blüm et al. (2024) review CAR T-cell therapy’s clinical implications and limitations, noting that infection risk remains a critical barrier to broader application. They highlight the need for integrated infectious disease expertise in CAR T-cell programs.

Kahraman et al. (2021) contextualize infection risks in hematologic malignancy patients undergoing allogeneic stem cell transplantation, with parallels applicable to CAR T-cell recipients, including prophylaxis strategies and infection surveillance protocols.

Farrington et al. (2026) address clinical and psychosocial changes in adults undergoing CAR T-cell therapy, noting that infection-related complications significantly impact quality of life and functional recovery.

Caveats and uncertainty

Most data derive from observational cohorts and expert consensus; randomized controlled trials specifically addressing infection prevention in CAR T-cell therapy remain limited.

Heterogeneity in CAR T-cell products, conditioning regimens, and patient comorbidities complicates standardized infection risk stratification.

Optimal timing and choice of antimicrobial prophylaxis, especially antifungals and antivirals, require further study.

Distinguishing infection from CAR T-cell–related inflammatory toxicities remains challenging and may delay diagnosis.

Long-term infection risks post-CAR T-cell therapy are incompletely characterized.

How this may change practice

Clinicians should adopt multidisciplinary approaches incorporating infectious disease specialists early in CAR T-cell therapy planning and follow-up.

Pre-treatment dental evaluation and management should be standard to reduce oral infection risks.

Risk-adapted antimicrobial prophylaxis protocols, including antifungal agents, should be implemented based on patient-specific factors and institutional epidemiology.

Enhanced surveillance for bacterial, viral, and fungal infections is warranted throughout the CAR T-cell therapy continuum.

Education of patients and caregivers on infection signs and prompt reporting is critical.

Future research should focus on refining prophylaxis strategies and diagnostic algorithms to improve infection outcomes.


References

  1. Penack O, et al. Management of Patients Undergoing CAR-T Cell Therapy in Germany. Oncol Res Treat 2024;47(3):123-131. DOI:10.1159/000536201
  2. Bupha-Intr O, et al. CAR-T cell therapy and infection: a review. Expert Rev Anti Infect Ther 2021;19(7):837-848. DOI:10.1080/14787210.2021.1855143
  3. Zadik Y, et al. MASCC/ISOO Clinical Practice Statement: dental evaluation and management prior to treatment for hematologic malignancies and CAR T-cell therapy. Support Care Cancer 2025;33(2):789-797. DOI:10.1007/s00520-025-09845-4
  4. Özkocaman V, et al. Antifungal Management in Patients with Hematological Malignancies: From Primary Prophylaxis to Empirical and Diagnosis-Driven Treatment. Turk J Haematol 2026;43(1):1-14. DOI:10.4274/tjh.galenos.2026.32559
  5. Kahraman S, et al. Infections in Patients with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantations. Cancer Ther Oncol Int J 2021;19(1):556019. DOI:10.19080/ctoij.2021.19.556019
  6. Blüm P, et al. Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations. Cancers 2024;16(8):1599. DOI:10.3390/cancers16081599
  7. Farrington AG, et al. Clinical, Functional, And Psychosocial Changes In Adults With Hematologic Malignancies Undergoing CAR T-cell Therapy. Med Sci Sports Exerc 2026;58(1):45-52. DOI:10.1249/01.mss.0001261292.74499.a8

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team